Table 1.
Characteristics of the overall study population
| Variables | No Paxlovid (n = 209, 44.47%) | Late Paxlovid (n = 120, 25.53%) | Early Paxlovid (n = 141, 30.00%) | p Value |
|---|---|---|---|---|
| Age (years) | 75 (67−86) | 78 (66−86) | 80 (70−88) | 0.056 |
| Time to negative conversion of viral RNA (days) | 16 (12−21) | 15 (13−19) | 11 (9−14) | <0.001 |
| Hospital stay (days) | 12 (10−16) | 12 (9−15) | 12 (10−14) | 0.241 |
| Sex | 0.776 | |||
| Female | 115 (46.0%) | 62 (24.8%) | 73 (29.2%) | |
| Male | 94 (42.7%) | 58 (26.4%) | 68 (30.9%) | |
| COVID‐19 vaccine received | 0.289 | |||
| 0 | 143 (42.3%) | 88 (26.0%) | 107 (31.7%) | |
| 1 | 66 (50.0%) | 32 (24.2%) | 34 (25.8%) | |
| Hypertension | 0.628 | |||
| No | 87 (46.0%) | 50 (26.5%) | 52 (27.5%) | |
| Yes | 122 (43.4%) | 70 (24.9%) | 89 (31.7%) | |
| Diabetes | 0.216 | |||
| No | 154 (42.9%) | 90 (25.1%) | 115 (32.0%) | |
| Yes | 55 (49.5%) | 30 (27.0%) | 26 (23.4%) | |
| Coronary artery disease | 0.176 | |||
| No | 162 (44.3%) | 100 (27.3%) | 104 (28.4%) | |
| Yes | 47 (45.2%) | 20 (19.2%) | 37 (36.6%) | |
| Cerebrovascular disease | 0382 | |||
| No | 170 (45.9%) | 94 (25.4%) | 106 (28.6%) | |
| Yes | 39 (39.0%) | 26 (26.0%) | 35 (35.0%) | |
| Chronic obstructive pulmonary disease | 0.872 | |||
| No | 192 (44.1%) | 112 (25.7%) | 131 (30.1%) | |
| Yes | 17 (48.6%) | 8 (22.9%) | 10 (28.6%) | |
| Chronic kidney disease | 0.063 | |||
| No | 195 (43.3%) | 117 (26.0%) | 138 (30.7%) | |
| Yes | 14 (70.0%) | 3 (15.0%) | 3 (15.0%) | |
| Severity status of COVID‐19 | 0.612 | |||
| Mild | 97 (42.4%) | 59 (25.8%) | 73 (31.9%) | |
| Moderate | 112 (46.5%) | 61 (25.3%) | 68 (28.2%) | |
| Fever | 0.422 | |||
| No | 163 (43.2%) | 96 (25.5%) | 118 (31.3%) | |
| Yes | 46 (49.5%) | 24 (25.8%) | 23 (24.7%) | |
| Cough | 0.125 | |||
| No | 52 (40.9%) | 28 (22.0%) | 47 (37.0%) | |
| Yes | 157 (45.8%) | 92 (26.8%) | 94 (27.4%) | |
| Sputum | 0.087 | |||
| No | 80 (41.2%) | 45 (23.2%) | 69 (35.6%) | |
| Yes | 129 (46.7%) | 75 (27.2%) | 72 (26.1%) | |
| Myalgia | 0.058 | |||
| No | 189 (43.1%) | 116 (26.4%) | 134 (30.5%) | |
| Yes | 20 (64.5%) | 4 (12.9%) | 7 (22.6%) | |
| Headache | 0.882 | |||
| No | 207 (44.5%) | 119 (25.6%) | 139 (29.9%) | |
| Yes | 2 (40.0%) | 1 (20.0%) | 2 (40.0%) | |
| Dyspnea | 0.987 | |||
| No | 195 (44.5%) | 112 (25.6%) | 131 (29.9%) | |
| Yes | 14 (43.8%) | 8 (25.0%) | 10 (31.3%) | |
| Diarrhea | 0.193 | |||
| No | 206 (44.4%) | 117 (25.2%) | 141 (30.4%) | |
| Yes | 3 (50%) | 3 (50%) | 0 (0%) | |
| Treatment with glucocorticoid | 0.591 | |||
| No | 203 (44.9%) | 115 (25.4%) | 134 (29.6%) | |
| Yes | 6 (33.3%) | 5 (27.8%) | 7 (38.9%) |
Note: Data are presented as number (%), or median (interquartile range). Continuous variables use Kruskal−Wallis test and categorical variables use χ 2 test for comparing the characteristics of three groups.